# University of Erlangen-Nürnberg Medical School

Organization · id `cardio:org-university-of-erlangen-nurnberg-medical-school` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov sponsor names](<https://clinicaltrials.gov/search?spons=University+of+Erlangen-N%C3%BCrnberg+Medical+School>), retrieved 18 November 2026. No person wrote or checked this page.

## In plain language

An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.

## Technical summary

Sponsor class other. No ROR record matches the name exactly.

## The registry's words

- Sponsor name: University of Erlangen-Nürnberg Medical School
- Sponsor class: OTHER

## Connected pages

- Sponsors: Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes (`cardio:ct-nct02752113`)
- Sponsors: Effect of Evolocumab on Vascular Function (`cardio:ct-nct03626831`)
- Sponsors: Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes (`cardio:ct-nct05303857`)

## Provenance

Content hash: a5d59d52044c3a7bda141903d1e200905de943125c3b50d92d0e6c4a42cf5b1b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
